Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P10415 (
Bcl-2
)
33,771
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Cellular oncogenes have been shown to play crucial roles in the cell death process induced by cytotoxic agents. In this study, we have demonstrated that v-H-ras transformed NIH 3T3 cells but not other transformants (v-raf, v-src, v-erbB-2, v-fes and v-mos) exhibited a survival advantage to treatment by a DNA-damaging agent, methylmethanesulfonate (MMS). Subsequently, the biochemical and morphologic criteria of MMS-treated cells were examined. It was found that MMS induced v-H-ras transformants to go through necrosis, but it induced other transformed cells to undergo apoptosis. The levels of glutathione (
GSH
) within each transformant as well as in NIH 3T3 cells, were determined. The results showed that
GSH
levels within ras transformants were 2- to 7-fold higher than the levels in other transformants and normal NIH 3T3 cells. By using the
GSH
synthesis inhibitor buthionine sulfoximine,
GSH
levels were artificially reduced. This depletion, however, made ras transformed cells more sensitive to MMS killing, but the mode of cell death was still necrosis. Western blot analysis demonstrated that the anti-apoptotic protein
Bcl-2
was constitutively expressed in ras transformed cells but not in NIH 3T3 or other transformed cells. The level of
Bcl-2
was correlated with the resistant phenotype of ras transformants during MMS treatment. These observations suggest that
GSH
and
Bcl-2
levels may cooperatively confer the resistant phenotype of ras transformants in response to MMS. In addition, the mode of cell death may possibly be determined at least in part by
Bcl-2
protein.
...
PMID:Differential induction of apoptosis in oncogene-transformed NIH 3T3 cells by methylmethanesulfonate. 868 3
Recent evidence suggests that apoptotic deletion of activated mature lymphocytes is an essential physiological process implicated in both the regulation of the immune response and the control of the overall number of immunocompetent cells. Tightly interrelated signaling mechanisms convey either activation or death messages, achieving the necessary equilibrium between cell proliferation and cell deletion. During the course of aging, numerous alterations of these signaling pathways may shift the balance toward cell death. In the present investigation, the reduced DNA synthesis of anti-CD3 activated T lymphocytes isolated from elderly individuals is associated with an important and early cell deletion from the cultures. Visualization of DNA fragmentation in the remaining activated cells argues in favour of the apoptotic nature of the cell deletion. Quantification of histone-associated DNA fragments shows that the apoptotic process is greatly amplified in activated lymphocytes derived from senescent organisms. Further analysis reveals that IL-2 deprivation does not play a significant role in the age-related increase in apoptosis. Partial correction of this excessive apoptosis by products that bypass the early steps of the signaling cascade suggests that transmembrane signaling defects are involved in this process. Exploration of the antioxidant pathway reveals that the increased susceptibility of lymphocytes from senescent organisms to apoptosis is not explained by a decreased
Bcl-2
expression and is not influenced by a modification of the intracellular concentration of glutathione (
GSH
).
...
PMID:Excessive apoptosis of mature T lymphocytes is a characteristic feature of human immune senescence. 880 91
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries but the clinical presentation and rate of disease progression are highly variable. When treatment is required the most commonly used therapy is the nitrogen mustard alkylating agent, chlorambucil (CLB), with or without prednisone. Although CLB has been used in the treatment of CLL for forty years the exact mechanism of action of this agent in CLL is still unclear. Studies in proliferating model tumor systems have demonstrated that CLB can bind to a variety of cellular structures such as membranes, RNA, proteins and DNA; however, DNA crosslinking appears to be most important for antitumor activity in these systems. In addition, a number of different mechanisms can contribute to CLB resistance in these tumor models including increased drug metabolism, DNA repair and CLB detoxification resulting from elevated levels of glutathione (
GSH
) and glutathione S-transferase (GST) activity. However, unlike tumor models in vitro, CLL cells are generally not proliferating and studies in CLL cells have raised questions about the hypothesis that DNA crosslinking is the major mechanism of antitumor action for CLB in this disease. CLB induces apoptosis in CLL cells and this appears to correlate with the clinical effects of this agent. Thus, alkylation of cellular targets other than DNA, which can also induce apoptosis, may contribute to the activity of CLB. Alterations in genes such as p53, mdm-2, bcl-2 and bax which control entry into apoptosis may cause drug resistance. Loss of wild-type p53 by mutation or deletion occurs in 10 to 15% of CLL patients and appears to correlate strongly with poor clinical response to CLB. The induction of apoptosis by CLB is paralleled by an increase in P53 and Mdm-2 but this increase in not observed in patients with p53 mutations indicating that with high drug concentrations CLB can produce cell death through P53 independent pathways. The level of Mdm-2 mRNA in the CLL cells is not a useful predictor of drug sensitivity. In addition, although Bax and
Bcl-2
are important regulators of apoptosis and the levels of these proteins are elevated in CLL cells compared with normal B cells, the levels of Bax and
Bcl-2
, or the Bax:
Bcl-2
ratio, are not important determinants of drug sensitivity in this leukemia. Finally, whereas CLB and nucleoside analogs may produce cell death in CLL by a P53 dependent pathway other agents, such as dexamethasone or vincristine, may act through P53-independent pathways.
...
PMID:Chlorambucil in chronic lymphocytic leukemia: mechanism of action. 903 Oct 99
Activated interleukin-2 (IL-2)-dependent T cells express high levels of
Bcl-2
protein. On cytokine withdrawal,
Bcl-2
expression decreases and the cells die rapidly by apoptosis. We have previously shown that the survival of IL-2-deprived T cells can be promoted by factor(s) secreted by fibroblasts. Here we report that reduced glutathione (
GSH
), but not its oxidized counterpart GSSG, also enhances the in vitro survival of these cells. Exogenous
GSH
mediates its effect intracellularly, as (1) endogenous glutathione concentrations are increased up to fivefold in the presence of
GSH
, and (2) acivicin, an inhibitor of transmembrane
GSH
transport, abrogates
GSH
-dependent survival. The
GSH
-rescued T cells do not proliferate and express only low levels of
Bcl-2
, resembling W138 fibroblast-rescued T cells. We, therefore, investigated a role for
GSH
in fibroblast-promoted T-cell survival. We show that W138-promoted survival results in elevated
GSH
levels in surviving T cells and is abrogated by buthionine sulfoximine (BSO), an inhibitor of
GSH
synthesis. Furthermore, both W138-promoted T-cell survival and
GSH
upregulation are associated with large molecular weight molecules (>30 kD). Thus, the upregulation of
GSH
by W138 fibroblasts appears to be crucial in their ability to enhance the survival of cytokine-deprived activated T cells in vitro.
...
PMID:Upregulation of intracellular glutathione by fibroblast-derived factor(s): enhanced survival of activated T cells in the presence of low Bcl-2. 911 89
According to current understanding, several metabolic alterations form part of the common phase of the apoptosis process. Such alterations include a disruption of the mitochondrial transmembrane potential (delta psi(m)), a depletion of nonoxidized glutathione (
GSH
) levels, an increase in the production of reactive oxygen species (ROS), and an elevation in cytosolic free Ca2+ levels. Using a cytofluorometric approach, we have determined each of these parameters at the single cell level in thymocytes or T cell hybridoma cells undergoing apoptosis. Regardless of the apoptosis induction protocol (glucocorticoids, DNA damage, Fas cross-linking, or CD3epsilon cross-linking), cells manifest a near-to-simultaneous delta psi(m) dissipation and
GSH
depletion early during the apoptotic process. None of the protocols for apoptosis inhibition (antioxidants, delta psi(m) stabilization,
Bcl-2
hyperexpression, or inhibition of IL-1-converting enzyme) allowed for the dissociation of delta psi(m) disruption and
GSH
depletion, indicating that both parameters are closely associated with each other. At a later stage of the apoptotic process, cells manifest a near-simultaneous increase in ROS production and intracellular Ca2+ levels. Whereas the thapsigargin- or ionophore-induced elevation of calcium levels has no immediate consequence on delta psi(m') cellular redox potentials, or ROS production, pro-oxidants and menadione, an inducer of mitochondrial superoxide anion generation, cause a rapid (15 min) Ca2+ elevation. Together, these data suggest a two-step model of the common phase of apoptosis. After an initial delta psi(m) dissipation linked to
GSH
depletion (step 1), cells hyperproduce ROS with an associated disruption of Ca2+ homeostasis (step 2).
...
PMID:Glutathione depletion is an early and calcium elevation is a late event of thymocyte apoptosis. 914 73
The mechanism by which
Bcl-2
oncogene expression inhibits radiation-induced apoptosis has been investigated in two mouse lymphoma cell lines: line LY-as is radiation sensitive, displays substantial radiaton-induced apoptosis, and expresses low levels of
Bcl-2
; line LY-ar is radiation-resistant, displays a low apoptosis propensity, and expresses 30-fold higher amount of
Bcl-2
protein than does the sensitive line. We observed that upon incubation in cystine/methionine-free (C/M-) medium, radiation-induced apoptosis in the LY-ar cells was restored to levels comparable to that seen in the LY-as cells. lntracellular glutathione (
GSH
) concentrations in LY-ar cells incubated in C/M- medium plummeted to 50% of control values within 2 h. LY-ar cells treated with diethyl maleate (DEM) or diamide, agents that deplete cellular thiols, had increased susceptibility to radiation-induced apoptosis in a manner similar to C/M- medium. These results are consistent with the general idea that
Bcl-2
expression blocks apoptosis through an antioxidant pathway that involves cellular thiols. That
Bcl-2
-expressing tumor cells can be sensitized by exogeneous agents that modify cellular thiols offers strategies for overcoming such resistance.
...
PMID:Resistance to radiation-induced apoptosis in Bcl-2-expressing cells is reversed by depleting cellular thiols. 933 22
In this study we used HeLa cells transfected with a conditional
Bcl-2
expression construct to study the effects of
Bcl-2
on reduced glutathione (
GSH
) metabolism. Our previous work demonstrated that depletion of
GSH
by culturing cells in tissue culture medium lacking the amino acids cysteine and methionine, essential for
GSH
biosynthesis, caused cells overexpressing
Bcl-2
to become sensitized to apoptotic induction. Here we report that
Bcl-2
also dramatically alters
GSH
compartmentalization. Cellular distribution of
GSH
, assayed by confocal microscopy, revealed that when
Bcl-2
expression was suppressed
GSH
was uniformly distributed primarily in the cytosol, whereas overexpression of
Bcl-2
led to a relocalization of
GSH
into the nucleus. Isolated nuclei readily accumulated radiolabeled
GSH
and maintained higher nuclear
GSH
concentration in direct relation to
Bcl-2
nuclear protein levels. Moreover, exogenous
GSH
blocked apoptotic changes and caspase activity in isolated nuclei exposed to the pro-apoptotic protease granzyme B. Our results indicate that one of the functions of
Bcl-2
is to promote sequestration of
GSH
into the nucleus, thereby altering nuclear redox and blocking caspase activity as well as other nuclear alterations characteristic of apoptosis. We speculate that this mechanism contributes to the suppression of apoptosis in cells with elevated
Bcl-2
levels.
...
PMID:Bcl-2 expression causes redistribution of glutathione to the nucleus. 950 Nov 97
Two Hep G2 subclones overexpressing CYP2E1 were established with the use of transfection and limited dilution screening techniques. The Hep G2-CI2E1-43 and -47 (E47) cells (transduced Hep G2 subclones that overexpress CYP2E1) grew at a slower rate than parental Hep G2 cells or control subclones that do not express CYP2E1, but remained fully viable. When
GSH
synthesis was inhibited by treatment with buthionine sulfoximine,
GSH
levels rapidly declined in E47 cells but not control cells, which is most likely a reflection of CYP2E1-catalyzed formation of reactive oxygen species. Under these conditions of
GSH
depletion, cytotoxicity and apoptosis were found only with the E47 cells. Low levels of lipid peroxidation were found in the E47 cells, which became more pronounced after
GSH
depletion. The antioxidants vitamin E, vitamin C, or trolox prevented the lipid peroxidation as well as the cytotoxicity and apoptosis, as did transfection with plasmid containing antisense CYP2E1 or overexpression of
Bcl-2
. Levels of ATP were lower in E47 cells because of damage to mitochondrial complex I. When
GSH
was depleted, oxygen uptake was markedly decreased with all substrates in the E47 extracts. Vitamin E completely prevented the decrease in oxygen uptake. Under conditions of CYP2E1 overexpression, two modes of CYP2E1-dependent toxicity can be observed in Hep G2 cells: a slower growth rate when cellular
GSH
levels are maintained and a loss of cellular viability when cellular
GSH
levels are depleted. Elevated lipid peroxidation plays an important role in the CYP2E1-dependent toxicity and apoptosis. This direct toxicity of overexpressed CYP2E1 may reflect the ability of this enzyme to generate reactive oxygen species even in the absence of added metabolic substrate.
...
PMID:Cytotoxicity and apoptosis produced by cytochrome P450 2E1 in Hep G2 cells. 954 53
Tumor necrosis factor-alpha (TNFalpha)-induced cell death involves a diverse array of mediators and regulators including proteases, reactive oxygen species, the sphingolipid ceramide, and
Bcl-2
. It is not known, however, if and how these components are connected. We have previously reported that
GSH
inhibits, in vitro, the neutral magnesium-dependent sphingomyelinase (N-SMase) from Molt-4 leukemia cells. In this study,
GSH
was found to reversibly inhibit the N-SMase from human mammary carcinoma MCF7 cells. Treatment of MCF7 cells with TNFalpha induced a marked decrease in the level of cellular
GSH
, which was accompanied by hydrolysis of sphingomyelin and generation of ceramide. Pretreatment of cells with
GSH
,
GSH
-methylester, or N-acetylcysteine, a precursor of
GSH
biosynthesis, inhibited the TNFalpha-induced sphingomyelin hydrolysis and ceramide generation as well as cell death. Furthermore, no significant changes in
GSH
levels were observed in MCF7 cells treated with either bacterial SMase or ceramide, and
GSH
did not protect cells from death induced by ceramide. Taken together, these results show that
GSH
depletion occurs upstream of activation of N-SMase in the TNFalpha signaling pathway. TNFalpha has been shown to activate at least two groups of caspases involved in the initiation and "execution" phases of apoptosis. Therefore, additional studies were conducted to determine the relationship of
GSH
and the death proteases. Evidence is provided to demonstrate that depletion of
GSH
is dependent on activity of interleukin-1beta-converting enzyme-like proteases but is upstream of the site of action of
Bcl-2
and of the execution phase caspases. Taken together, these studies demonstrate a critical role for
GSH
in TNFalpha action and in connecting major components in the pathways leading to cell death.
...
PMID:Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death. 955 24
Beta-Lapachone a novel topoisomerase inhibitor, has been found to induce apoptosis in various human cancer cells. In this study we report that a dramatic elevation of hydrogen peroxide (H2O2) in human leukemia HL-60 cells following 1 microM beta-lapachone treatment and that this increase was effectively inhibited by treatment with antioxidant N-acetyl-L-cysteine (NAC), ascorbic acid, alpha-tocopherol. NAC strongly prevented beta-lapachone-induced apoptotic characteristics such as DNA fragmentation and apoptotic morphology. However, treatment of HL-60 cells with another topoisomerase inhibitor camptothecin (CPT) did not induce H2O2 production as compared to untreated cells. NAC also failed to block CPT-induced apoptosis. Correlated with these findings, we found that cancer cell lines K562, MCF-7, and SW620, contained high level of intracellular glutathione (
GSH
), were not elevated in H2O2 and were resistant to apoptosis after treatment with beta-lapachone. In contrast, cancer cell lines such as, HL-60, U937, and Molt-4 which have lower level of
GSH
, were readily increased of H2O2 and were sensitive to this drug. Furthermore, ectopic overexpression of
Bcl-2
in HL-60 cells also attenuated beta-lapachone-induced H2O2 and conferred resistance to beta-lapachone-induced cell death. Beta-Lapachone at the concentration as low as 0.25 microM effectively induced HL-60 cells to undergo monocytic differentiation, as evidenced by CD14 antigenicity and alpha-naphthyl acetate esterase activity. Again, the beta-lapachone-induced monocytic differentiation was suppressed by NAC. These results suggest that intracellular H2O2 generation plays a crucial role in beta-lapachone-induced cell death and differentiation.
...
PMID:Involvement of hydrogen peroxide in topoisomerase inhibitor beta-lapachone-induced apoptosis and differentiation in human leukemia cells. 955 79
1
2
3
4
5
6
7
8
9
10
Next >>